Inhibition of TrkA is also known to alleviate pain in rodent models of carrageenan and collagen-induced arthritis58, but clinical trials to treat osteoarthritis pain with tanezumab, a monoclonal antibody against NGF, were discontinued because of a higher risk of joint damage despite reduced pain59. Here, NTRK1 is linked to osteoarthritis.